Forward Therapeutics Announces $50 Million Series A Financing To Advance Next-Generation Small Molecule Immune Therapies
Forward Therapeutics Announces $50 Million Series A Financing To Advance Next-Generation Small Molecule Immune Therapies
11/08/23, 12:02 PM
Location
palm beach gardensMoney raised
$50 million
Industry
biopharma
therapeutics
pharmaceutical
biotechnology
health care
Round Type
series a
Investors
Orbi Med, Ra Capital Management, Bvf Partners Lp
Forward Therapeutics, Inc., a biopharmaceutical company developing next-generation small molecule therapies for chronic immunological and inflammatory disorders, today announced a $50 million Series A financing. The financing was led by BVF Partners LP with participation from other leading life sciences investors RA Capital Management and OrbiMed.